Cargando…

Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against Ovarian Cancer

Chimeric antigen receptors (CARs) have found clinical success in B cell malignancies, but a dearth of potential targets limits their wider clinical application, especially in solid tumours. Here, we describe the development of an anti-annexin A2 CAR, CAR(2448), derived from an antibody found to have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leong, Leonard, Tan, Heng Liang, Cua, Simeon, Yong, Kylie Su Mei, Chen, Qingfeng, Choo, Andre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013580/ https://www.ncbi.nlm.nih.gov/pubmed/31936170 http://dx.doi.org/10.3390/ijms21020381

Ejemplares similares

Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448
por: Cua, Simeon, et al.
Publicado: (2018)

In vivo surveillance and elimination of teratoma‐forming human embryonic stem cells with monoclonal antibody 2448 targeting annexin A2
por: Tan, Heng Liang, et al.
Publicado: (2019)

Preclinical testing of chimeric antigen receptor T cells in neuroblastoma mouse models
por: Li, Nan, et al.
Publicado: (2021)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma
por: Perez-Amill, Lorena, et al.
Publicado: (2020)

Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer
por: Tan, Heng Liang, et al.
Publicado: (2018)

Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation
por: Proics, Emma, et al.
Publicado: (2022)

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer
por: Yan, Wenying, et al.
Publicado: (2019)

Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment
por: Terlikowska, Katarzyna M., et al.
Publicado: (2021)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Biomarkers in individualized management of chimeric antigen receptor T cell therapy
por: Du, Mengyi, et al.
Publicado: (2020)

Preclinical evaluation of chimeric antigen receptor T cells targeting the carcinoembryonic antigen as a potential immunotherapy for gallbladder cancer
por: Lopez, Ernesto, et al.
Publicado: (2023)

Recombinant and Chimeric Disintegrins in Preclinical Research
por: David, Victor, et al.
Publicado: (2018)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor
por: Chen, K H, et al.
Publicado: (2017)

Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
por: Qin, Haiying, et al.
Publicado: (2018)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

Humanized CD30-Targeted Chimeric Antigen Receptor T Cells Exhibit Potent Preclinical Activity Against Hodgkin’s Lymphoma Cells
por: Guo, Jing, et al.
Publicado: (2022)

P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
por: Meinke, S., et al.
Publicado: (2022)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer
por: Tang, Lu, et al.
Publicado: (2023)

Generation of Chimeric Antigen Receptors against Tetraspanin 7
por: Pieper, Tom, et al.
Publicado: (2023)

The annexins
por: Moss, Stephen E, et al.
Publicado: (2004)

Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins
por: Gou, Rui, et al.
Publicado: (2019)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Tetraploid embryonic stem cells can contribute to the development of chimeric fetuses and chimeric extraembryonic tissues
por: Wen, Bingqiang, et al.
Publicado: (2017)

ANO5 ensures trafficking of annexins in wounded myofibers
por: Foltz, Steven J., et al.
Publicado: (2021)

Preparation and Evaluation of Human-Murine Chimeric Antibody against Protective Antigen of Bacillus anthracis
por: Hao, Lina, et al.
Publicado: (2014)

Canonical Wnt signaling activation by chimeric antigen receptors for efficient cardiac differentiation from mouse embryonic stem cells
por: Sogo, Takahiro, et al.
Publicado: (2023)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Assessment of chimeric antigen receptor T cytotoxicity by droplet microfluidics in vitro
por: Wong, Kuan Un, et al.
Publicado: (2022)

CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience
por: Palomba, M Lia, et al.
Publicado: (2022)

Human V(H)-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC
por: Kolluri, Aarti, et al.
Publicado: (2023)

Current and future perspectives of chimeric antigen receptors against glioblastoma
por: Zhang, Josephine, et al.
Publicado: (2022)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44
por: Klapdor, Rüdiger, et al.
Publicado: (2021)

Development of chimeric antigen receptor-redirected T cell therapy targeting L1-CAM in ovarian cancer
por: Hong, Hao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rdd73u99raj334jfoa30iqb8s7